Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Non-GAAP Cost of Sales: $12,027M in FY2025, down 2.1% from a year earlier.
Latest, FY2025
12,027
Period ended Dec 31, 2025
Change on a year earlier
-2.1%
12,289 in FY2024
History
5 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Cost of sales | $ | 16,382 | 2,871 | 1,484 | 4,355 | $ | 12,027”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 2a.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Cost of Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12,027 | -2.1% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 12,289 | -11.6% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 13,897 | -8.3% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 15,147 | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2020 | Dec 31, 2020 | 9,828 | – | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
Breakdown
What makes up non-GAAP Cost of Sales
Cite this data
StockData. (2026). Merck Non-GAAP Cost of Sales ($M), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/nongaap-cos
See every metric in the Merck KPI table. Data updated Oct 26, 2026.